Navigation Links
MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
Date:12/20/2011

ROCKVILLE, Md., Dec. 20, 2011 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, announced today that it will receive a milestone payment from Boehringer Ingelheim.  The milestone payment was triggered as part of an agreement executed in October 2010 to discover, develop and commercialize antibody-based therapeutics based on MacroGenics' Dual-Affinity Re-Targeting (DART) platform.  The amount of the milestone payment remained undisclosed.  Therapeutics in the global alliance will be directed against up to ten combinations of molecular targets and may span multiple therapeutic areas, including immunology, oncology, respiratory, cardiometabolic and infectious diseases.  To date, MacroGenics has achieved five pre-clinical milestones across both of its DART collaborations with Boehringer Ingelheim and Pfizer, Inc.

Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics, commented: "We are very encouraged by the progress we've made with this DART candidate in collaboration with Boehringer Ingelheim."  Dr. Koenig continued, "MacroGenics expects to advance multiple product candidates from this alliance in 2012 and beyond."

About MacroGenics
MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for cancer, autoimmune disorders and infectious diseases. The company has built a fully-integrated set of capabilities in antibody-based product development which supports its innovative pipeline of clinical stage product candidates. MacroGenics' proprietary research is based on three core technology platforms, which include: (1) a leading research capability for screening and targeting cancer stem-like cells; (2) Dual-Affinity Re-Targeting (or DART) bispecific technology, which allows the incorporation of multiple specificities within a single recombina
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients With HER2-Expressing Solid Tumors
2. MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer
3. MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding Further Advances DART Platform and Infectious Disease Portfolio
4. MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
5. Paulo F. Costa Joins MacroGenics Board of Directors
6. MacroGenics Appoints New Vice President of Business Development
7. MacroGenics Raises $25M in Series D-2 Financing
8. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
9. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
10. Watsons Generic Yaz(R) Receives FDA Approval
11. UCSB professor receives award for graphene electronics research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Graphite Metallizing Corporation announces GRAPHALLOY® ... These bearings are uniquely suited to prevent loss of ... of the high temperatures . , Recently, a ... design engineers at Graphite Metallizing to overcome problems with ... manufacturing operation, pans containing blocks of powder mixture are ...
(Date:7/31/2014)... 2014 CollabRx, Inc. (NASDAQ: CLRX), a ... in oncology, today announced that it will hold an ... the Company's financial results for the first quarter of ... business in the current fiscal year. , The dial-in ... August 14, 2014, at 5 p.m. EDT (2 p.m. ...
(Date:7/31/2014)... Francisco, Calif. (PRWEB) July 31, 2014 ... newly diagnosed patients with an overview of the disease ... management of drug side effects, as well as updates ... “We’re grateful to Dr. Sandy Srinivas for organizing this ... survivor of kidney cancer. “Sandy and her colleagues have ...
(Date:7/31/2014)... “Rapid technological advances will spread ... increasing unemployment, depressing American consumer spending and further ... Catch 22—we need automated manufacturing if we are ... says economist and corporate relocation expert Dr. Ron ... Pro-Business States for 2014, co-published with the American ...
Breaking Biology Technology:Graphite Metallizing Announces Bearings for High Temperature Oven Applications 2Graphite Metallizing Announces Bearings for High Temperature Oven Applications 3CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 2ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 3ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 4
... , ... /PRNewswire-Asia-FirstCall/ --,China Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: CYXN; ... and,retailer of pharmaceuticals in Northeastern China, today announced it ... Drug List. , The Chinese ...
... , SEATTLE, Nov. 30 ... announced today that its new class of platinum-based anti-tumor ... activity compared to currently available platinum-based compounds as well ... lines. The results were presented in a paper ...
... ... Elsevier, the world,s,leading publisher of scientific, medical and technical products and services,today ... million indexed records from more than 7,000,active, peer reviewed journals. , ... new biomedical,and pharmaceutical insights. Now, new developments and updates include: , , ...
Cached Biology Technology:China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 3
(Date:7/31/2014)... lurks beneath many of the roughly 156,000 gas ... is corrosion in parts of underground gas storage ... contamination of groundwater, a source of drinking water. ... have reported many rapidly corroding gas storage tank ... generally associated with use of gasoline-ethanol blends and ...
(Date:7/31/2014)... An experimental vaccine protected 100 percent of animal models ... difficile , which causes an intestinal disease that kills ... of print in Infection and Immunity . ... and non-human primates against the purified toxins produced by ... orogastric spore infection, a laboratory model that mimics the ...
(Date:7/31/2014)... been made to help better identify and treat those with ... and enlarging of medium sized arteries in the body, which ... causing damage. In a new report appearing in August 2014 ... provide evidence that that FMD may not be limited to ... connection to abnormalities of bones and joints, as well as ...
Breaking Biology News(10 mins):NIST corrosion lab tests suggest need for underground gas tank retrofits 2C. difficile vaccine proves safe, 100 percent effective in animal models 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2
... 25-year non-stop research expeditioninto the deep ocean. Over the ... are completing the installation off the British Columbia coast of ... observatory. Using three ships and at least one ROV, ... 400 instruments and sensors to the seafloor where they are ...
... Van Andel Research Institute (VARI) investigators ... therapeutic target in the treatment of the most aggressive ... have few treatment options. "Breast cancer mortality rates ... to traditional treatments tend to be more aggressive and ...
... For the first time, an international group of researchers ... of DNA on chromosome 6. This is the ... The LSUHSC research team was led by Nancy Buccola, APRN, ... Sciences Center New Orleans, who also coordinated the ten clinical ...
Cached Biology News:World's largest ocean observatory takes shape 2World's largest ocean observatory takes shape 3Possible drug target found for one of the most aggressive breast cancers 2LSUHSC research helps link schizophrenia to specific DNA region 2
...
Mouse monoclonal antibody raised against a partial recombinant ZNF155. NCBI Entrez Gene ID = ZNF155...
... Bio-Beads SM-2 adsorbents are macroporous polystyrene beads ... high surface area for adsorbing organics of ... solutions. The beads are useful for the ... agents; for example, the removal of detergents ...
... Anti-Mi-2 Immunogen : Fusion ... residues 474-970 of human Mi-2 ... 0.105M NaCl, 0.035% sodium azide, ... routinely evaluated by immunoblot on ...
Biology Products: